Effect of B7.1 Costimulation on T-Cell Based Immunity against TAP-Negative Cancer Can Be Facilitated by TAP1 Expression by Li, Xiao-Lin et al.
Effect of B7.1 Costimulation on T-Cell Based Immunity
against TAP-Negative Cancer Can Be Facilitated by TAP1
Expression
Xiao-Lin Li
1, Yong-Yu Liu
3, David Knight
1, Yoshinobu Odaka
1, J. Michael Mathis
1, Runhua Shi
2, Jonathan
Glass
2, Qian-Jin Zhang
1*
1Department of Cellular Biology and Anatomy, Gene Therapy Program, Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center, Shreveport,
Louisiana, United States of America, 2Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States of America,
3College of Pharmacy, Basic Pharmaceutical Sciences, University of Louisiana, Monroe, Louisiana, United States of America
Abstract
Tumors deficient in expression of the transporter associated with antigen processing (TAP) usually fail to induce T-cell-
mediated immunity and are resistant to T-cell lysis. However, we have found that introduction of the B7.1 gene into TAP-
negative (TAP
2) or TAP1-transfected (TAP1
+) murine lung carcinoma CMT.64 cells can augment the capacity of the cells to
induce a protective immune response against wild-type tumor cells. Differences in the strength of the protective immune
responses were observed between TAP
2 and TAP1
+ B7.1 expressing CMT.64 cells depending on the doses of c-irradiated
cell immunization. While mice immunized with either high or low dose of B7.1-expressing TAP1
+ cells rejected TAP
2 tumors,
only high dose immunization with B7.1-expressing TAP
2 cells resulted in tumor rejection. The induced protective immunity
was T-cell dependent as demonstrated by dramatically reduced antitumor immunity in mice depleted of CD8 or CD4 cells.
Augmentation of T-cell mediated immune response against TAP
2 tumor cells was also observed in a virally infected tumor
cell system. When mice were immunized with a high dose of c-irradiated CMT.64 cells infected with vaccinia viruses carrying
B7.1 and/or TAP1 genes, we found that the cells co-expressing B7.1 and TAP1, but not those expressing B7.1 alone, induced
protective immunity against CMT.64 cells. In addition, inoculation with live tumor cells transfected with several different
gene(s) revealed that only B7.1- and TAP1-coexpressing tumor cells significantly decreased tumorigenicity. These results
indicate that B7.1-provoked antitumor immunity against TAP
2 cancer is facilitated by TAP1-expression, and thus both genes
should be considered for cancer therapy in the future.
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Introduction
One effective strategy against cancer is the induction of CD8
+
T-cell immunity [1]. However, tumors deficient in major
histocompatibility complex class I (MHC-I) antigen presentation
often evade immune-mediated destruction [2,3,4,5]. Deficiency in
TAP expression is frequently observed in human cancer [2,3].
TAP is composed of TAP1 and TAP2 subunits whose function is
to transport cytosolic-generated peptides into the lumen of the
endoplasmic reticulum (ER) for MHC-I binding, followed by
transport of MHC-I/peptide complexes to the cell surface. Lack of
TAP expression (one or both subunits) in tumor cells generally
inhibits expression of TAP-dependent peptide antigens on the cell
surface, resulting in failure of CD8
+ T-cell recognition.
Although presentation of TAP-dependent peptide antigens is
limited, TAP-deficient cells are able to present TAP-independent
antigens. For example, mouse T-lymphoma RMA-S cells which
express only TAP1 [6] and human T and B hybrid T2 cells which
lack both TAP1 and TAP2 genes [7] can present some MHC-I
restricted TAP-independent antigens derived from proteins
located in or outside the ER lumen [8,9,10,11,12,13]. Different
capacities for antigen presentation are also observed between
TAP-negative and TAP1-positive tumor cells. Gabathuler, R et al.
report that introduction of the TAP1 gene into TAP-negative
tumor cells changes the mode of antigen presentation to resemble
that of TAP1-positive RMA-S cells, as indicated by the fact that a
virally-derived antigen can be efficiently presented on the surface
of TAP1-possitive but not TAP-negative tumor cells [14]. Even
though TAP-independent antigens can be presented by TAP1-
positive or TAP-negative tumor cells, failure of the cells to
efficiently induce a large population of tumor-antigen specific
CD8
+ T-cell effectors may be a major reason limiting efficacy of
antitumor immunity. Such antitumor immunity can be augmented
by introducing a B7.1 gene into TAP-deficient tumor cells as
reports indicated [13,15].
B7.1 is a costimulatory molecule that interacts with CD28 on T
lymphocytes and plays an important role in immune induction.
Tumors transduced with B7.1 can elicit CD8
+ T-cell dependent
PLoS ONE | www.plosone.org 1 July 2009 | Volume 4 | Issue 7 | e6385antitumor responses [16,17,18]. In particular, B7.1 transfected
TAP1-expressing RMA-S cells can elicit T-cell clones reacting
with TAP1 or TAP2 deficient tumor cells, but not with TAP-
competent tumor cells [13]. One such T-cell clone recognizes an
ER-localized-Lass5-protein-derived antigen that is presented
exclusively by RMA-S and other TAP1 or TAP2 deficient cells
and protects mice from RMA-S tumor challenge [13]. These
studies provide useful information regarding the priming of T-cell
based immunity against tumor immune escape variants in cancer
immunotherapy. However, in many cases, human cancer exhibits
a TAP-negative phenotype, and thus it is still unclear whether
B7.1 expression in these tumor cells can elicit the protective T-cell
immunity or whether expression of both B7.1 and TAP1 genes is
required to generate such immunity.
In this study, we used a murine lung carcinoma CMT.64 cell
line as a model cell system to address this question. The CMT.64
cells are defective in both TAP1 and TAP2 at transcriptional and
translational levels and express low levels of MHC-I molecules
[14,19]. We tranfected the CMT.64 cells with either B7.1 gene
alone or B7.1 together with mouse TAP1 genes, and found that
transfectants induced different antitumor immune responses. B7.1
and TAP1 co-expression in tumor cells significantly decreases their
tumorigenicity while B7.1 expression alone in the cells has no
change. However, both B7.1-expressing and B7.1 and TAP1 co-
expressing cells dramatically increased the capacity for generation
of protective immunities at the high dose of tumor immunization.
At the low dose of tumor immunization, only B7.1 and TAP1 co-
expressing cells provided protective immunity. These results
suggest that B7.1 and TAP1 co-expression in tumor cells is
important for T-cell priming.
Results
B7.1 and TAP1 expression decreases tumorigenicity of
TAP-deficient CMT.64 cells only in T-cell competent mice
To evaluate the effects of B7.1 expression on TAP1-positive and
TAP-negative tumor cells on antitumor immunity, we first
analyzed expression of the introduced genes in CMT.64
transfectants. CMT.64/pp, CMT.B7.1/p, CMT.TAP1/p,
CMT.TAP1/B7.1 and CMT.TAP1,2 cl.21 cells were transfected
with two empty vectors, B7.1+empty vector, TAP1+empty vector,
TAP1+B7.1 or TAP1+TAP2, respectively (see Material and
Methods for detail). After drug selection, the transfectants
expressed the relevant gene(s), except for a CMT.64/pp
transfectant which did not show TAP1, TAP2 or B7.1 expression
(Fig.1A and 1B). Gene expression was stable during the time of
study. K
b and D
b expression in most transfectants was similar to
wild-type CMT.64 cells, except for CMT.TAP1,2 cl.21 cells which
expressed K
b and D
b molecules at levels higher than that
expressed in the others (Fig. 1C).
To assess whether B7.1 expression in the tumor cells could
decrease tumorigenicity, C57BL/6 mice were injected with live
CMT.64 cells or transfectants, and survival rates and/or times
were recorded. Results are shown in Fig. 2A. All mice injected i.p.
with CMT.64 or CMT.64/pp cells (2 control groups) died before
day 27 after tumor cell inoculation. In contrast with two controls,
CMT.TAP1/B7.1-bearing mice showed a highly significant
survival rate (P%0.05), even compared with all other mouse
groups (P%0.05). At day 100, 30% of the mice were still alive.
However, CMT.B7.1/p-bearing mice showed no significant
difference, compared to two control groups (P.0.05).
CMT.TAP1/p-bearing mice showed significant survival time
compared to the two controls (P,0.05) but no difference from
the CMT.B7.1/p-bearing mice (P.0.05). Results of this experi-
ment demonstrate that a substantial decrease in tumorigenicity is
mediated by expression of B7.1 together with TAP1 molecules in
CMT.64 tumor cells.
To determine if decreased tumorigenicity of CMT.TAP1/B7.1
cells was mediated by T cells, nude mice were inoculated with
CMT.64 cells or transfectants, and survival was determined.
Figure 2B shows that all mice died at 25–27 days, suggesting that
T cells played an essential role in the immune response against
CMT.TAP1/B7.1 cells, resulting in a decrease in tumorigenicity.
CMT.B7.1/p-immunization at a high dose induces an
immune response as efficient as CMTTAP1/B7.1-
immunization but is less efficient at a low dose
Antitumor immune responses can be augmented by B7.1-
expressing tumor cell immunization [16,17,18]. To assess whether
protective immunity against TAP-negative tumor cells can be
generated by immunization with either TAP1-expressing
CMT.TAP1/B7.1 cells or TAP-negative CMT.B7.1/p cells,
C57BL/6 mice were immunized with different amounts of c-
irradiated cells followed by challenge with CMT.64 cells. Control
mice were immunized with c-irradiated CMT.64/pp cells. Results
indicate a dose-dependent protection. At the high dose of
immunization (5610
6 cells per mouse), both CMT.TAP1/B7.1-
immunized and CMT.B7.1/p-immunized mice were well pro-
tected from live tumor attack (Fig. 2C left-panel). The two mouse
groups showed a highly significant survival rate (100% survivors),
compared with the CMT.TAP1/p-immunized mouse group (60%
survivors, p,0.05). The latter group showed a survival rate
significantly higher than a control group immunized with TAP-
negative CMT.64/pp cells (P%0.05). However, at the low dose of
immunization (5610
5 cells per mouse), CMT.TAP1/B7.1-immu-
nized mice had a survival rate higher than CMT.B7.1/p-
immunized mice (Fig. 2C right-panel, P,0.05). No difference in
survival rate was observed between CMT.B7.1/p-immunized and
CMT.TAP1/p-immunized mice (P.0.05). Results suggest that at
the high dose of immunization, B7.1 and TAP1 co-expression or
B7.1 expression alone renders tumor cells potent immunogens,
while at low dose immunization, potent immunogenicity requires
tumor cells co-expressing both TAP1 and B7.1 molecules.
CD8
+ T cells play an important role in mouse protection
To determine if the increased protection after B7.1-expressing
tumor immunization was mediated by a T-cell based immune
response, we used mAbs to deplete CD8
+ or CD4
+ T cells in
C57BL/6 mice before immunization and tumor cell challenge.
Mice injected i.p. with relevant mAb every other day for the first
week were analyzed by FACS assays for CD8
+ or CD4
+ T-cell
population in blood. Results showed that the treatment dramat-
ically decreased the CD8
+ T-cell or CD4
+ T-cell population
(Fig. 3A). Anti-CD8 specific mAb treatment reduced CD8
+ T cells
from 17.66% to 0.65%, and anti-CD4 specific mAb treatment
reduced CD4
+ T cells from 19.22% to 0.11%. T-cell subpopu-
lation depleted mice were injected with c-irradiated CMT.64
transfectants, followed by challenge with live CMT.64 cells.
Survival results are shown in Fig. 3B. The anti-CD8 specific mAb
treatment significantly decreased the survival of tumor-bearing
mice. There was no biologically significant difference between
each tested-group and the control group (CMT.64/pp-immunized
mice). In addition, the anti-CD4 specific mAb treatment partially
decreased survival of each tested-group, compared with the
control group (P%0.05). Results suggest that protection of mice
from tumor challenge fully depended on CD8
+ T cells and
partially depended on CD4
+ T cells.
TAP-Independent Tumor Immunity
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deficient tumor cells
The fact that TAP-deficient B7.1-expressing tumor cells can
generate a CD8
+ T-cell mediated immune response against TAP-
negative tumor cells suggests that the tumor cells present TAP-
independent antigen(s) for T-cell priming. To determine if this is true,
we focused on the D
b-restricted Lass5 epitope MCLRMTAVM, an
antigen presented by many TAP-deficient cells [13]. CMT.64 and
Figure 1. Expression of TAP1, B7.1 and MHC-I molecules in transfectants. TAP, B7.1, K
b and D
b expression in CMT.64 transfectants was
determined. A) TAP1 and TAP2 proteins were detected in CMT.64 transfectants and control RMA cells by Western blots using anti-TAP1 and TAP2
polyclonal antibodies respectively (see Material and Methods). Levels of expression of GAPDH protein were detected in each sample as the loading
control. B) B7.1 expression in CMT.B7.1/p and CMT.TAP1/B7.1 cells was detected by FACS assays using FITC-conjugated B7.1-specific mAb 16-10A1.
Control is CMT.64 cells stained with mAb 16-10A1. C) K
b or D
b expression was detected by FACS assays using primary mAbs Y-3 against H-2K
b or 28-
14-8S against H-2D
b followed by staining with a FITC-conjugated goat anti-mouse IgG secondary Ab. CMT.64 cells stained with a primary mAb 15-5-
5S (against H-2D
k) followed by staining with a FITC-conjugated goat anti-mouse IgG secondary Ab were used as a negative control. a: negative
control; b: CMT.64; c: CMT.64/pp; d: CMT.B7.1/p; e: CMT.TAP1/p; f: CMT.TAP1/B7.1; and g: CMT.TAP1,2 cl.21.
doi:10.1371/journal.pone.0006385.g001
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time PCR (Fig. 4A left). However, TAP-negative and TAP1-
transfected CMT.64 cells but not TAP-competent CMT.TAP1,2
cl.21 cells were killed by a T-cell population generated by
immunization with Lass5 peptide pulsed RMA-S/B7.1 cells as
determined by a prolonged (12–16 h)
51Cr-release assay (Fig. 4A
right). The TAP-competent CMT.TAP1,2 cl.21 cells were killed only
when they were pulsed with Lass5 peptide (Fig. 4A right), suggesting
that the cells did not efficiently present this epitope.
Since the T-cell population was generated by RMA-S/B7.1
cells pulsed with Lass5 peptide, we cannot exclude the possibility
that the T-cell population contains sub-populations of other
epitope-specific T cells that kill TAP-deficient tumor cells. This is
because the RMA-S/B7.1 cells used for immunization have been
reported to be able to generate many different K
b and D
b
restricted T-cell clones [13]. To eliminate this possibility, we
generated a D
b-restricted influenza NP366–374 (ASNENMDTM)
epitope specific T-cell population by immunization with RMA-S/
B7.1 cells pulsed with NP366–374 peptide using conditions similar to
those for Lass5 specific T-cell generation. Tumor cells do not
express influenza NP366–374 epitope and thus NP366–374 epitope
specific T cells should not recognize the tumor cells. If the T-cell
population contains NP366–374 epitope irrelevant T cells, such a T-
cell population can either kill TAP-deficient tumor cells or fail to
kill the cells. If the T-cells kill the tumor cells this suggests that
TAP-independent epitope specific T-cells, other than NP366–374
Figure 2. Decrease in tumorigenicity and increase in immune response by B7.1 and TAP1 co-expressing tumor cells. The time of
morbidity was recorded for mice (each group, n=10) inoculated with live tumor cells or immunized with c-irradiated cells and followed by challenge
with CMT.64 cells. Statistics for mouse survival were obtained using the Kaplan–Meier log rank survival test and differences were considered
significant at P,0.05. A) Tumorigenicity was detected by injection of C57BL/6 mice i.p. with live CMT.64 cells or their transfectants (5610
4 cells per
mouse). B) Nude mice were used for determination of tumorigenicity with conditions of tumor injection the same as shown in A), P.0.05 for all
comparisons. C) C57BL/6 mice were immunized i.p. with different c-irradiated tumor cells or PBS at a high-dose (left, 5610
6 cells per mouse) or a low-
dose (right, 5610
5 cells per mouse). After a 20-day immunization, the mice were challenged i.p. with live CMT.64 tumor cells (2.5610
5 cells per
mouse). Different survival rates and/or times were observed.
doi:10.1371/journal.pone.0006385.g002
TAP-Independent Tumor Immunity
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cells pulsed with the NP366–374 peptide. If the T-cells do not kill the
tumor cells this suggests that the peptide-pulsed RMA-S/B7.1 cells
generate a T-cell population containing T-cells that preferentially
recognize the peptide epitope used for immunization. Results show
that the generated T cells cannot kill either TAP-deficient or TAP-
competent tumor cells except for CMT.64 cells pulsed with
NP366–374 peptide (Fig. 4B left). Thus, our results confirm that
Figure 3. Deduction or abolishment of immune response against CMT.64 tumor by depleting CD4
+ or CD8
+ T cell sub-population in
C57BL/6 mice. Mice (each group, n=10) were injected i.p. with mAbs GK1.5 for CD4
+ T cells or 2.43 for CD8
+ T cells (0.1 ml per mouse) every other
day for the first week and once per week afterward to deplete relevant T-cell sub-population. A) Before c-irradiated tumor cell immunization,
depletion of CD8
+ or CD4
+ T cell subsets was assessed in blood by FACS assays using FITC-conjugated anti-mouse CD8a (5H1-1) or FITC-conjugated
anti-mouse CD4 (RM4-4) together with PE/Cy5-conjugated anti-mouse CD3 (145-2C11). Frequencies of CD8
+ or CD4
+ T cells were detected before
mAb treatment (indicated as normal) and after first week mAb treatment and before c-irradiated tumor cell immunization (indicated as mAb-
treatment). B) After a 20-day immunization with c-irradiated tumor cells (5610
6 cells per mouse) the mice were challenged i.p. with live CMT.64
tumor cells (2.5610
5 cells per mouse). The time of morbidity was recorded.
doi:10.1371/journal.pone.0006385.g003
TAP-Independent Tumor Immunity
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spliced (long and short) Lass5 gene transcripts [13] in CMT.64, CMT.TAP1,2, cl.2 and RMA-S cells. Only the long transcript encodes a Lass5 epitope [13].
A) Right: Lass5 epitope presentation by TAP-deficient and TAP-proficient CMT.64 cells was detected by 12–16 h
51Cr-release assays. Lass5 specific T
cells were generated by immunization i.p with c-irradiated RMA-S/B7.1 cells pulsed with 5 mM Lass5 peptide. The immunized splenocytes were re-
stimulated in vitro with Lass5 peptide-pulsed c-irradiated RMA-S/B7.1 cells for 5 days. One of three experiments is shown. B) Left: 12–16 h
51Cr-release
assays were conducted to confirm that an NP366–374 eptitope specific T-cell population generated by immunization with c-irradiated RMA-S/B7.1 cells
pulsed with 5 mMN P 366–374 peptide did not contain T-cell sub-populations recognizing TAP-independent epitopes presented by CMT.64 and its
transfectants. The
51Cr-labled targets were shown in figure 4B. B) Right: Standard
51Cr-release assays were conducted to confirm that TAP-deficient
CMT.64 transfectants did not present TAP-dependent NP366–374 epitope when the cells were infected overnight with VV carrying NP366–374 minigene
at multiplicity of infection (MOI) of 3. The
51Cr-labled targets were shown in figure 4B. The NP366–374 epitope specific T-cells were generated by
immunization with c-irradiated RMA-S/B7.1 cells pulsed with 5 mMN P 366–374 peptide and re-stimulated with 5 mMN P 366–374 peptide in vitro. C) An
ELISPOT assay was performed to detect Lass5 specific IFN-c-secreting precursors. Mice were immunized with c-irradiated CMT.64/pp, CMT.TAP1,2,
CMT.B7.1/p and CMT.TAP1/B7.1 tumor cells. The immunized splenocytes were stimulated with or without Lass5 peptide. The number of Lass5
antigen-specific, IFN-c-secreting precursors was determined. Precursor frequency is reported as IFN-c-secreting cells per 10
6 splenocytes (IFN-c-SC/
10
6 splenocytes).
doi:10.1371/journal.pone.0006385.g004
TAP-Independent Tumor Immunity
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recognition. In contrast with TAP-independent Lass5 epitope
presentation, TAP-deficient tumor cells were unable to present the
TAP-dependent and D
b-restricted NP366–374 epitope when cells
were infected with VV carrying the NP366–374 minigene (Fig.4 B
right).
To determine if CMT.TAP1/B7.1, CMT.B7.1/p,
CMT.TAP1/p and CMT.64/pp cells are able to elicit Lass5
specific T cells, the cells were injected i.p into C57BL/6 mice, and
IFN-c secreting splenocytes were quantified using an ELISPOT
assay. As shown in Fig. 4C, a large increase in the number of Lass5
specific IFN-c secreting splenocytes was observed in mice
immunized with either CMT.TAP1/B7.1 or CMT.B7.1/p cells
compared with mice immunized with CMT.TAP1/p or
CMT.64/pp cells. These results indicate that TAP-negative and
TAP1-expressing tumor cells can present TAP-independent
antigens, including Lass5 antigen and that B7.1 expression in
the tumor cells provides better T-cell priming.
Immunization with CMT.64 cells infected with both VV-
B7.1 and VV-TAP1 increases protection of mice from
tumor challenge
A potential method for more reliable cancer immunotherapy is
use of a viral-based gene-carrying vector to infect cells for
immunization. Since immunization with a high dose of B7.1 or
B7.1+TAP1 transfected cells dramatically protected mice from
tumor challenge (Fig. 2C left), we determined if immunization of
mice with c-irradiated CMT.64 cells infected with VV-B7.1+VV-
CR19 (wild-type virus) or VV-B7.1+VV-TAP1 have protection
similar to mice immunized with gene-transfected tumor cells. We
first analyzed B7.1 and TAP1 expression in CMT.64 cells infected
overnight with VV-B7.1+VV-CR19 or VV-B7.1+VV-TAP1. We
observed that B7.1 and TAP1 were highly expressed in the cells
infected with relevant VVs (Fig. 5A).
Wild-type VV infection may inhibit antigen presentation in
dendritic cells [20] and decrease infected cell viability. To avoid
these effects, we used a recombinant VV-GFP to substitute wild-
type VV-CR19 for viral-based cell infection and immunization.
Mice were immunized i.p. with CMT.64 cells (5610
6 cells/mouse)
infected with VV-GFP+VV-GFP, VV-B7.1+VV-GFP, or VV-
B7.1+VV-TAP1, followed by challenge with live CMT.64 cells
and survival rates were determined. Results are shown in Table 1.
Mice immunized with VV-B7.1+VV-TAP1 infected CMT.64 cells
showed a significantly increased survival rate, compared with mice
immunized with the cells infected with VV-GFP+VV-GFP
(control mice; P,0.05), while no difference was observed between
control mice and mice immunized with the cells infected with VV-
B7.1+VV-GFP (P.0.05). These results indicate that for immuni-
zation with a virally infected cell system, co-expression of B7.1 and
TAP1 in cells is necessary to augment protective anti-tumor
immunity.
Since immunization with cells expressing B7.1 alone showed
different protective T-cell mediated immune responses between a
virally infected cell system and a gene-transfected cell system at a
dose of 5610
6 cells per mouse immunization, we speculated that
virally derived antigens affect presentation of TAP-independent
intrinsic tumor antigens, thereby decreasing the capacity of tumor
cells for T-cell priming. To evaluate this possibility, standard
51Cr-
release assays were conducted using cytolytic T cells generated by
immunization with c-irradiated CMT.B7.1/p cells (5610
6 cells/
mouse). CMT.64 cells infected with VV-B7.1+VV-TAP1, VV-
B7.1+VV-GFP or VV-GFP+VV-GFP overnight were used as
targets and VV-uninfected CMT.64, CMT.B7.1/p and
CMT.TAP1/B7.1 cells were used as controls. As shown in
Fig. 5B, recognition of the virally infected cells by T cells was
significantly reduced, compared to relevant controls.
Taken together, we conclude that effective vaccination with
virally infected TAP-negative cells requires both B7.1 and TAP1
co-expression in the tumor cells.
Discussion
This study demonstrates that B7.1 and TAP1 co-expression in
TAP-negative CMT.64 cells renders tumor cells potent immuno-
gens able to effectively induce a CD8
+ T-cell mediated immune
response against TAP-negative tumors. Induced CD8
+ T cells
likely recognize TAP-independent antigens presented by TAP-
deficient tumor cells. Three important factors, TAP1, B7.1 and the
amount of antigen(s) appear to contribute to CMT.64 tumor cell
priming of T cells.
Our results indicate that with a low dose of c-irradiated cell
immunization, the TAP1 and B7.1 co-expressing CMT.TAP1/
B7.1 cells generated an antitumor immune response greater than
that induced by the TAP-negative and B7.1 expressing
CMT.B7.1/p cells (Fig. 2C right). This indicates that TAP1
expression plays a critical role in enhancing T-cell priming which
suggests that TAP1 expression may facilitate efficient presenta-
tion of TAP-independent tumor antigens. The possibility of
efficient presentation of the antigen(s) is supported by Fig. 5B
(lanes b and c) which shows that CMT.B7.1/p-induced T cells
killed CMT.TAP1/B7.1 targetsb yb e t t e rt h a nC M T . B 7 . 1 / p
targets. A possible mechanism of increased antigen presentation
by TAP1 is that its expression ‘supports’ presentation of some
antigens (other than ER-lumen-derived antigens which can be
presented by both TAP-negative and TAP1-postive cells) that are
expressed on the cell surface for T-cell recognition and/or T-cell
priming. This possibility is supported by evidence that a vesicular
stomatitis virus nucleocapsid protein derived epitope VSV-Np52-
59 which is generated in the cytoplasm can be presented by TAP1
expressing CMT.64 cells more efficiently than TAP-negative
CMT.64 cells [14]. Our findings highlight the multiplicity of
immune responses against tumors, which are in-built into the
cellular immune system. The significance of these findings should
be studied further, especially for identification of TAP-indepen-
dent epitopes that are well-presented and for characteristics of
epitope specific T cells.
B7.1 expression in tumor cells may play a role in decreasing the
threshold for antigen-specific T-cell priming [21,22,23]. This
possibility is supported by our observation that T-cell mediated
anti-CMT.64 tumor immunity can be augmented by B7.1
expressing tumor cells compared with B7.1 negative tumor cells
(Fig. 2C left). Mechanisms involved in priming of T cells against
CMT.64 tumors by B7.1 expressing TAP-deficient cells may be
preferentially through tumor direct priming rather than dendritic
cell (DC) cross-priming. This explains why immunization with
B7.1 expressing CMT.64 cells induced a high level of anti-
CMT.64-tumor immunity while immunization with B7.1-negative
CMT.64 cells provided significantly less immunity. Cross-priming
requires professional antigen presenting DCs to capture antigenic
proteins from apoptotic cells and to process and present the
generated epitopes for T-cell priming in a TAP-dependent manner
[24]. Thus, TAP-independent epitopes which are expressed on
CMT.64 cells may not be presented on the DC’s surface for T-cell
priming, because these epitopes similar to the peptides presented
on TAP-deficient RMA-S cells [25] generally display low ability
for MHC-I binding, and therefore cannot compete with TAP-
dependent epitopes for MHC-I binding and DC’s surface
expression.
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PLoS ONE | www.plosone.org 7 July 2009 | Volume 4 | Issue 7 | e6385Figure 5. Influence of TAP-independent tumor antigen presentation in virally infected TAP-deficient tumor cells. CMT.64 cells were
infected overnight with a combination of two VVs at MOI of 3 for each VV. A) B7.1 expression was detected by FACS assay using FITC-conjugated
B7.1-specific mAb 16-10A1. CMT.64 cells without viral infection were used as a negative control. TAP1 expression was detected by Western blot using
a goat anti-mouse TAP1 polyclonal Ab. RMA-S cells were used as a control. B) Standard
51Cr-release assays were conducted to detect if virally infected
tumor cells affected presentation of endogenous tumor antigens. CMT.64 tumor cells were infected overnight with VV-GFP+VV-GFP, VV-B7.1+VV-GFP,
or VV-B7.1+VV-TAP1, and used as target cells. Control cell lines were CMT.64, CMT.B7.1/p and CMT.TAP1/B7.1. Tumor antigen-specific T cells were
generated by immunization with c-irradiated CMT.B7.1/p cells. Target and effector ratio was used at 1:100. a: CMT.64; b: CMT.B7.1/p; c: CMT.TAP1/
B7.1; d: CMT.64+VV-GFP+VV-GFP; e: CMT.64+VV-B7.1+VV-GFP and f: CMT.64+VV-B7.1+VV-TAP1. ** indicates statistical significance (P%0.05) using
ANOVA analysis.
doi:10.1371/journal.pone.0006385.g005
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PLoS ONE | www.plosone.org 8 July 2009 | Volume 4 | Issue 7 | e6385The amount of antigen(s) used for immunization directly affects
the strength of generated antitumor immunity as confirmed by our
results regarding dose-dependent immunization with c-irradiated
cells (Fig. 2C left and right). With a high dose cell immunization,
highly protective immunities were generated by both
CMT.TAP1/B7.1 and CMT.B7.1/p cells. This suggests that
both c-irradiated cell lines supplied efficient amounts of TAP-
independent antigens for T-cell induction. With a low dose
immunization, TAP1-positive CMT.TAP1/B7.1 cells stimulated
the immune system to generate protective immunity better than
TAP-negative CMT.B7.1/p cells. This suggests that TAP1 and
B7.1 co-expressing CMT.TAP1/B7.1 cells provide TAP-indepen-
dent antigens for T-cell priming more than that provided by B7.1
expressing CMT.B7.1/p cells.
A recent report illustrated that immunization with B7.1-
transfected TAP1-expressing RMA-S cells elicited T-cell based
protective immunity against RMA-S cells [13]. Our results further
show that immunization with either TAP1-expressing or TAP-
negative tumor cells that express B7.1 can elicit an effective T-cell
mediated immune response against TAP-negative tumor chal-
lenge. In such protective immunity, CD8
+ T cells played a major
role in the response to TAP-negative tumor cells, while CD4
+ T
cells had a significant role as well. Since CMT.64 cells do not
express MHC class II molecules, a major function of CD4
+ T cells
may be to support CD8
+ T-cell responses to tumor cells
[26,27,28,29,30,31,32] or through a cytokine release mechanism
to accumulate and activate effector cells [33]. NK activity may not
play a major role in the immune response against CMT.64 tumor
cells, as we did not observe high protective immunity in cell-
immunized experiments in which the CD8
+ T-cell population only
was depleted by antibody, whereas the NK population should
have been present (Fig. 3B left).
We have confirmed that TAP-deficient CMT.64 transfectants
are able to present TAP-independent Lass5 epitope and that with
B7.1 expression, such cells can elicit Lass5-specific T cells. These
results provide direct evidence for an immune response against a
TAP-independent antigen. Although tumor cells can present the
Lass5 epitope and elicit T cells, we believe that generation of tumor-
rejective T-cell mediated immunity may require another TAP-
independentantigen or multipleantigens forT-cellpriming because
the Lass5 epitope is presented at a low level in CMT.64 cells. Thisis
suggestedbytheprolonged time requirementforkillingthe cellsand
by the relatively low number of Lass5 antigen specific T cells.
In summary, B7.1 and TAP1 co-expression in TAP-negative
tumor cells provides two major advantages for induction of a T-
cell mediated antitumor immune response. TAP1 expression
affords tumor cells the ability to efficiently present TAP-
independent antigen(s) while B7.1 expression in tumor cells
decreases the threshold for priming of TAP-independent antigen
specific T cells. Thus, expression of both genes in tumor cells can
facilitate the induction phase of the T-cell based immune response.
Our findings may encourage the potential use of both genes for
cancer immunotherapy in the future.
Materials and Methods
Animals
C57BL/6 (H-2
b) and nude mouse (H-2
b) strains were obtained
from the NCI and housed in the animal facility at LSU Health
Sciences Center. All mice used for the experiments were 6–10 wk
old females and were maintained and treated in accordance with
the guidelines of the Animal Use Committee at LSU Health
Sciences Center.
Vectors
Wild-type vaccinia virus (VV) VV-CR19 [34] and recombinant
VV carrying an entire TAP1 gene (VV-TAP1), or influenza A
virus nucleoprotein minigene NP366–374 (VV-NP366–374) were
kindly provided by Dr. Yewdell, J (Laboratory of Viral Diseases,
National Institute of Allergy and Infectious Diseases, Bethesda,
MD). VV carrying a GFP gene (VV-GFP) was kindly provided by
Dr. Kirkegaard, K (Microbiology and Immunology, Stanford
University, School of Medicine, Stanford, CA). VV carrying a
B7.1 gene [35] (VV-B7.1) was kindly provided by Dr. Schlom, J
(Laboratory of Tumor Immunology and Biology, Center for
Cancer Research, Bethesda, MD). Mouse TAP1 and TAP2 cDNA
was inserted into the vectors pcDNA3.1/His and pUB6/V5-His
(Invitrogen Corporation, Carlsbad, CA) as described previously
[36]. A B7.1-vector [37] was provided by Dr. Li, S (Louisiana
State University, Baton Rouge, LA). B7.1 cDNA was isolated and
inserted into a pUB6/V5-His vector (Invitrogen Corporation).
Cell lines and cell culture
The mouse lung carcinoma cell line CMT.64-7 designated as
CMT.64 [38] was kindly provided by Dr. Gunnel Hallden
(Imperial College of Science, London, UK). CMT.64/pp,
CMT.B7.1/p, CMT.TAP1/p, CMT.TAP1/B7.1 and
CMT.TAP1,2 cl.21 (clone 21) cells were generated by co-
transfection of two empty vectors (pcDNA3.1/His and pUB6/
V5-His), B7.1+pcDNA3.1/His Vectors, TAP1+pUB6/V5-His,
B7.1+TAP1 vectors and TAP1+TAP2 vectors respectively.
Transfectants were maintained in DMEM medium containing
10% FBS, 1000 mg/ml neomycin and 20 mg/ml blasticidin
selection medium. CMT.64 cells were cultured in DMEM
medium while RMA and RMA-S cells were cultured in RPMI
1640 medium. RMA-S transfected with B7.1 (designated as RMA-
S/B7.1) cells were cultured with RPMI 1640 supplemented with
20 mg/ml blasticidin selection medium.
Detection of Lass5 expression by RT-PCR
Lass5 protein is an endoplasmic reticulum (ER)-membrane
spanning protein [13]. The Lass5 gene transcribes two mRNA
splice variants that include or exclude exon 9a and these two
variants are termed Lass5 long and short transcripts respectively
[13]. The long transcript encodes a Lass5 protein containing a D
b-
restricted epitope MCLRMTAVM at the protein C-terminal end
[13]. Lass5 short and long transcripts were detected by RT-PCR
Table 1. I n c r e a s e di m m u n ep r o t e c t i o no fm i c ef r o mT A P -
negativetumorchallenge byVV-B7.1+VV-TAP1-infectedCMT.64
cell immunization.
CMT.64 cells
infected with
Time (Days) 50%
mice survival
No. of Mouse Survival
at day 120
# P value*
VV-GFP+VV-GFP 32 1/10
VV-B7.1+VV-GFP 36 0/10 .0.05
VV-B7.1+VV-TAP1 79 4/10 ,0.05
C57BL/6 mice (each group, n=10) were immunized i.p with CMT.64 cells (5610
6
cells/mouse) infected overnight with VV-GFP+VV-GFP, VV-B7.1+VV-GFP, or VV-
B7.1+VV-TAP1 at MOI of 3 for each VV. After a 20-day immunization, mice were
challenged i.p. with live CMT.64 tumor cells (2.5610
5 cells/mouse), and the time
of morbidity was recorded.
#Experiments ended at day 120 of CMT.64 cell challenge.
*Indicated that the tested mouse groups compared with a control group
(immunized with VV-GFP+VV-GFP-infected CMT.64 cells) for statistical analysis
(ANOVA).
doi:10.1371/journal.pone.0006385.t001
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GAAGCTGCC-39 and the specific downstream primers 59-
CGGTCATCCTTAGACACATGCAAAGG-39 (for long tran-
script) or 59-CTGCGGTCATCCTTAGACACCTTTCC-39 (for
short transcript).
MHC-I and B7.1 expression
Surface MHC-I and B7.1 expression was detected by a
FACScan analyzer (Becton Dickinson, Mountain View, CA) using
direct and indirect immunofluorescence. For MHC-I expression,
cells were stained with an K
b-specific Y-3 primary monoclonal
antibody (mAb) (ATCC, Manassas, VA) or an D
b-specific 28-14-
8S primary mAb (ATCC) followed by staining with a FITC-
conjugated goat anti-mouse IgG secondary antibody (Ab) (Jackson
ImmunoResearch, West Grove, PA). CMT.64 cells stained with a
primary mAb 15-5-5S (against H-2D
k, ATCC) followed by
staining with a FITC-conjugated goat anti-mouse IgG secondary
antibody (Ab) were used as a negative control. For B7.1
expression, a FITC-conjugated anti-mouse CD80 mAb (clone
16–10A1 purchased from BioLegend) was used.
Detection of TAP
TAP protein was determined by Western blot using a goat anti-
mouse TAP1 polyclonal Ab (for TAP1, Santa Cruz Biotechnology,
Santa Cruz, CA) or mouse antiserum (for TAP2, generated in our
laboratory [36]). Western blot protocol was described previously
[36]. For a loading control, the levels of expression of the enzyme
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) protein was
detected in each sample as described previously [19,39].
Generation of cytolytic T lymphocytes (CTL) and
cytotoxicity tests
Antigen specific CTLs were generated by immunization of
C57BL/6 mice with c-irradiated RMA-S/B7.1 cells (1610
7 cells/
mouse) pulsed with 5 mM Lass5 peptide (for D
b-restricted Lass5-
CTLs) or pulsed with influenza NP366–374 (ASNENMDTM)
peptide (for D
b-restricted NP366–374-CTLs). Tumor-antigen spe-
cific CTLs were generated by immunization of C57BL/6 mice
with c-irradiated CMT.B7.1/p cells (5610
6 cells/mouse). After a
9-day immunization, the splenocytes were cultured with peptide or
c-irradiated and mitomycin-c-treated (30 mg/ml) cells for 5 days
and then used as effectors. For Lass5 antigen, the immunized
splenocytes were re-stimulated with Lass5-peptide pulsed RMA-S/
B7.1 cells (1610
7 cells/immunized-spleen) and 12–16 h
51Cr-
release assays were conducted. For tumor-antigen specific CTLs,
the immunized splenocytes were re-stimulated with CMT.B7.1/p
cells (1610
7 cells/immunized-spleen) and 4-h standard
51Cr-
release assays were conducted. For NP366–374-CTLs, the immu-
nized splenocytes were re-stimulated with either (1610
7 cells/
immunized-spleen) NP366–374-peptide pulsed RMA-S/B7.1 cells
(Figure 4B left) or with 5 mMN P 366–374 peptide (Figure 4B right).
12–16 h (Figure 4B left) or 4-h (Figure 4B right)
51Cr-release
assays were conducted. The
51Cr-labeled targets are described in
each figure or figure legend. Three experiments were performed
for each antigen or tumor cell type. One representative of three
experiments (Fig. 4) or the mean value (mean6SEM) from three
experiments (Fig. 5B) is shown.
ELISPOT analysis of TAP-independent Lass5 antigen-
specific INF-c secreting splenocytes
C57BL/6 mice were immunized i.p with c-irradiated tumor
cells (5610
6 tumor cells/mouse) two times (with a 12-day interval).
Nine days after the last immunization, splenocytes were isolated
and cultured in vitro in RPMI 1640 complete medium with or
without 5 mM Lass5 peptide MCLRMTAVM for 14 hours. The
frequency of Lass5 specific IFN-c secreting cells was determined
using an ELISPOT assay (R&D Systems, Minneapolis, MN)
according to the manufacturer’s instructions.
Detection of tumorigenicity and Tumor challenge
experiments
For detection of tumorigenicity, C57BL/6 mice or nude mice
(each group, n=10) were injected i.p. with 5610
4 tumor cells (in
500 ml PBS), and the time of morbidity was recorded. For tumor
challenge experiments, C57BL/6 mice (each group, n=10) were
immunized i.p. with c-irradiated tumor cells, and after a 20-day
immunization the mice were challenged i.p. with live CMT.64
tumor cells (2.5610
5 cells/mouse), and the time of morbidity was
recorded. Preparation of c-irradiated tumor cells for immunization
followed the procedures as shown below. CMT.64 transfectants
were c-irradiated at a 10000-rads irradiation dosage (for Fig. 2C
and Fig. 3B), or CMT.64 cells were infected with VVs overnight
(16 hours) followed by c-irradiation (10000-rads) and treatment
with mitomycin-c (30 mg/ml) for 2-hours. After extensive wash
with PBS, the cells (in 500 ml PBS per mouse) were inoculated i.p
into C57BL/6 mice. The number of cells used for immunization is
noted in each figure legend and table 1. Statistics for mouse
survival were obtained using the Kaplan–Meier log rank survival
test, and differences were considered significant at P,0.05. For in
vivo experiments, % survival was displayed in each figure, instead
of the time of morbidity. This is because the morbidity to death for
the mice inoculated i.p. with CMT.64 tumor cells was about 3–4
days. Therefore, the time of morbidity can refer to the survival
time extending 3–4 days.
Depletion of T cell sub-population in C57BL/6 mice using
relevant antibodies
Depletions of effectors in vivo were started 1 week before
vaccination. mAb GK1.5 or mAb 2.43 (ATCC, Manassas, VA)
was used for CD4 and CD8 depletions respectively [40]. mAb
purification and animal injection followed from a report [40] with
slight modification. Tissue cultured mAbs were purified using the
ammonium sulfate method and the purified mAbs had titers at
about 1:2000 by staining of splenocytes detected by FACS.
C57BL/6 mice were injected i.p with 0.1 ml/mouse mAb every
other day for the first week and once per week afterward.
Depletion of lymphocyte subsets was assessed in blood on and after
the day of tumor cell vaccination and live tumor challenge by
using FITC-conjugated anti-mouse CD8a (5H1-1) or FITC-
conjugated anti-mouse CD4 (RM4-4) together with PE/Cy5-
conjugated anti-mouse CD3 (145-2C11) (all from BioLegend).
After depletion of CD8
+ or CD4
+ T cell subsets, the mice were
immunized with c-irradiated tumor cells (5610
6 cells per mouse),
and after a 20-day immunization the mice were challenged with
live CMT.64 tumor cells (2.5610
5 cells per mouse). The time of
morbidity was recorded.
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